QL1706 Plus Lenvatinib in Previously Treated Penile Cancer
NCT07384416
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
47
Enrollment
OTHER
Sponsor class
Conditions
Penile Cancer
Interventions
DRUG:
QL1706 + Lenvatinib
Sponsor
Sun Yat-sen University